Rodolfo Trejo, MD
Family Medicine · Atlantis, FLNPI 1750335584
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 1,496 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,496 payments — averaging $26.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$7K
- AbbVie$5K
- GSK$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Pfizer$1K
- Amgen$1K
- plus $22K from 54 others
Across 295 payments — averaging $28,417 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$7.2M
- AstraZeneca$409K
- Sanofi US Services Inc.$345K
- Ionis Pharmaceuticals, Inc.$249K
- Teva Pharmaceuticals USA, Inc.$129K
- Biogen$29K
- plus $68K from 6 others
What the payments were for
- Food & beverage$39,670100%
- Education$1960%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,866 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 145 | $366,492 |
| EliquisApixaban | 250 | $178,393 |
| EnbrelEtanercept | 20 | $139,957 |
| RexultiBrexpiprazole | 70 | $114,186 |
| Humira(Cf) PenAdalimumab | 17 | $110,623 |
| FarxigaDapagliflozin Propanediol | 114 | $101,098 |
| RybelsusSemaglutide | 79 | $94,828 |
| OzempicSemaglutide | 88 | $84,523 |
| VraylarCariprazine Hcl | 56 | $84,148 |
| OtezlaApremilast | 16 | $73,740 |
| JardianceEmpagliflozin | 74 | $72,877 |
| XareltoRivaroxaban | 100 | $68,203 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 87 | $67,423 |
| LinzessLinaclotide | 76 | $58,923 |
| EntrestoSacubitril/Valsartan | 53 | $55,069 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,614 | $480,679215 claims |
| AmgenEnbrel, Otezla, Prolia | $1,444 | $262,47564 claims |
| AbbVieVraylar, Linzess, Creon | $4,630 | $184,805143 claims |
| Novo NordiskRybelsus, Ozempic | $1,388 | $179,352167 claims |
| PfizerEliquis | $1,450 | $178,393250 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $848 | $109,460144 claims |
| AstraZenecaFarxiga | $6,712 | $101,098114 claims |
| GileadBiktarvy, Descovy | $120 | $70,52723 claims |
| Johnson & JohnsonXarelto | $557 | $68,203100 claims |
| GSKTrelegy Ellipta | $1,777 | $67,42387 claims |
| NovartisEntresto | $770 | $55,06953 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,398 | $46,07215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Atlantis
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
- Giovana Rene CrooksBoca Raton$407K
- Edward BraunSt Petersburg$364K
- Samuel GreenleePensacola$235K
- Kevin FitzgeraldStuart$198K
- Louis KuritzkyGainesville$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.